Amicus Therapeutics (FOLD) Insider Trading & Ownership $9.58 -0.06 (-0.62%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$9.59 +0.01 (+0.05%) As of 01/31/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Amicus Therapeutics (NASDAQ:FOLD) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage2.20%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$1.30 M Get FOLD Insider Trade Alerts Want to know when executives and insiders are buying or selling Amicus Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address FOLD Insider Buying and Selling by Quarter Amicus Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/2/2024Bradley L CampbellCEOSell7,500$10.02$75,150.00 11/6/2024Bradley L CampbellCEOSell7,901$12.50$98,762.50 11/1/2024Bradley L CampbellCEOSell7,500$11.46$85,950.00 10/1/2024Bradley L CampbellCEOSell7,500$10.60$79,500.00 9/3/2024Bradley L CampbellCEOSell7,500$11.71$87,825.00 8/1/2024Bradley L CampbellCEOSell7,500$10.34$77,550.00 7/5/2024Bradley L CampbellCEOSell6,100$10.00$61,000.00 5/1/2024Bradley L CampbellCEOSell7,500$10.07$75,525.00 3/5/2024Margaret G McglynnDirectorSell7,500$13.40$100,500.00 2/15/2024Bradley L CampbellCEOSell4,167$14.00$58,338.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 2/15/2024David Michael ClarkInsiderSell4,427$14.00$61,978.00 2/15/2024John F CrowleyChairmanSell31,614$13.81$436,589.34 2/6/2024Ellen RosenbergInsiderSell400$13.00$5,200.00 (Data available from 1/1/2013 forward) FOLD Insider Trading Activity - Frequently Asked Questions Who is on Amicus Therapeutics's Insider Roster? The list of insiders at Amicus Therapeutics includes Bradley L Campbell, Daphne Quimi, David Michael Clark, Ellen Rosenberg, Jeff Castelli, John F Crowley, Margaret G Mcglynn, Michael Raab, and Samantha Prout. Learn more on insiders at FOLD. What percentage of Amicus Therapeutics stock is owned by insiders? 2.20% of Amicus Therapeutics stock is owned by insiders. Learn more on FOLD's insider holdings. Which Amicus Therapeutics insiders have been selling company stock? The following insiders have sold FOLD shares in the last 24 months: Bradley L Campbell ($2,745,156.46), David Michael Clark ($81,354.00), Ellen Rosenberg ($501,850.00), Jeff Castelli ($231,875.00), John F Crowley ($5,337,948.14), Margaret G Mcglynn ($100,500.00), Michael Raab ($49,942.64), and Samantha Prout ($1,055,059.09). How much insider selling is happening at Amicus Therapeutics? Insiders have sold a total of 793,112 Amicus Therapeutics shares in the last 24 months for a total of $10,103,685.33 sold. Amicus Therapeutics Key ExecutivesMr. Bradley L. Campbell M.B.A. (Age 48)CEO, President & Director Compensation: $984.09k5 recent tradesMs. Ellen S. Rosenberg (Age 61)Chief Legal Officer & Corporate Secretary Compensation: $733.94kMr. David M. Clark (Age 49)Chief People Officer Compensation: $701.39kDr. Jeffrey P. Castelli (Age 52)Chief Development Officer Compensation: $709.64kMr. Simon Nicolas Reade Harford (Age 64)Chief Financial Officer Ms. Samantha Prout (Age 46)Chief Accounting Officer & Controller Dr. Jill Weimer Ph.D.Chief Science OfficerAndrew FaughnanSenior Director of Investor RelationsMr. Patrik S. Florencio Esq.Global Chief Compliance & Risk OfficerMs. Diana MooreHead of Global Corporate Communications More Insider Trading Tools from MarketBeat Related Companies EXAS Insider Trades EXEL Insider Trades RGEN Insider Trades HALO Insider Trades MDGL Insider Trades IONS Insider Trades ALKS Insider Trades LGND Insider Trades GERN Insider Trades DVAX Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insider Selling in Tech Stocks Spikes in Q43 Small-Cap Stocks Insiders and Institutions Are Buying3 Stocks With Strong Capital Returns and Insider Buying SignalsZymeworks in Focus for Insider Activity: Catalysts AheadInsiders Are Loading Up: 3 Key Stock Picks for Investors This page (NASDAQ:FOLD) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
